4-Methyl-3'-fluor-trans-stilben | 38694-01-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-Methyl-3'-fluor-trans-stilben
• 英文别名: 1-fluoro-3-[(E)-2-(4-methylphenyl)ethenyl]benzene
• CAS: 38694-01-8
• 化学式: C₁₅H₁₃F
• 分子量: 212.267
• InChiKey: SSSMESAZOJHITE-MDZDMXLPSA-N

物化性质

• 沸点：
  306.4±22.0 °C(predicted)
• 密度：
  1.099±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-fluoro-3-(p-tolylethynyl)benzene 在 sodiumsulfide nonahydrate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 以93%的产率得到4-Methyl-3'-fluor-trans-stilben
  参考文献：
  名称：

  Transition-Metal-Free Semihydrogenation of Diarylalkynes: Highly Stereoselective Synthesis of trans-Alkenes Using Na₂S·9H₂O

  摘要：

  A highly stereoselective and efficient transition-metal-free semihydrogenation of internal alkynes to E-alkenes using cheap and green water as hydrogen donor is described. The reactions are conducted under convenient conditions and provide products in good to excellent yields, with broad substrate scope, including a variety of diarylalkynes.

  DOI：

  10.1021/ol501137x

文献信息

• [EN] COSMETIC COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSITIONS COSMÉTIQUES ET PROCÉDÉS D'UTILISATION
  申请人：STC UNM

  公开号：WO2020112998A1

  公开（公告）日：2020-06-04

  The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFKB and as agonists (activators) ofNrf2. In particular, these compounds show dual activity and it has been discovered that these compounds are particularly useful in the treatment of certain cosmetic applications and in rejuvenating and beautifying skin and other keratinous tissue of a subject in need. Cosmetic compositions and methods of using said compositions in combination with other components are disclosed herein.

  本发明涉及替代的stilbenes和dienones，表现出意外的双重活性，作为NFKB的抑制剂和Nrf2的激动剂。特别是，这些化合物展现了双重活性，已经发现这些化合物在治疗某些化妆品应用以及在使需要的主体的皮肤和其他角质组织恢复活力和美化方面特别有用。本文披露了化妆品组合物以及使用所述组合物与其他成分结合的方法。
• Activation of anti-oxidant Nrf2 signaling by substituted trans stilbenes
  作者：Lorraine M. Deck、Lisa J. Whalen、Lucy A. Hunsaker、Robert E. Royer、David L. Vander Jagt

  DOI：10.1016/j.bmc.2017.01.005

  日期：2017.2

  is the issue of selectivity. In the present study, substituted trans stilbenes were identified as activators of Nrf2. These activators of Nrf2 are not highly electrophilic and therefore are unlikely to activate Nrf2 through covalent modification of Keap1. Dose-response studies demonstrated that a range of substituents on either ring of the trans stilbenes, especially fluorine and methoxy substituents

  Nrf2是cap'n'collar转录因子家族的成员，是II期排毒和抗氧化基因以及抗炎和神经保护基因的主要调节剂。在许多慢性疾病中炎症和氧化应激的重要性支持了抗氧化剂Nrf2信号转导可能具有治疗潜力的概念。许多Nrf2激活剂已进入临床试验。Nrf2与它的结合伴侣Keap1结合存在于胞质溶胶中，Keap1是一种富含硫醇的氧化还原传感蛋白。响应于氧化和亲电子应力，Keap1的选定半胱氨酸残基被修饰，从而将Keap1锁定在Nrf2-Keap1复合物中，并使新合成的Nrf2进入细胞核。激活Nrf2的多种化学物质，包括多种天然产物，是亲电试剂，通常通过迈克尔加成来修饰Keap1，从而导致Nrf2激活。作为Keap1的亲电子共价修饰剂的Nrf2活化剂的设计，一个需要关注的问题是选择性问题。在本研究中，替代反式斯蒂芬苯酯被鉴定为Nrf2的激活剂。这些Nrf2激活剂不是高度亲电的，因此不太可能通过Keap
• [EN] ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING<br/>[FR] ANALOGUES DE LA FÉXARAMINE ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2015138969A1

  公开（公告）日：2015-09-17

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  揭示了具有化合物配方实施例的小说化合物，制备方法的实施例，以及包含它们的组合物。还揭示了一种治疗或预防受试者代谢紊乱的方法实施例，包括向受试者（例如，通过胃肠道）施用所述化合物的一种或多种治疗有效量，从而激活肠道中的FXR受体，并治疗或预防受试者的代谢紊乱。此外还揭示了一种治疗或预防受试者肠道区域炎症的方法实施例，包括向受试者（例如，通过胃肠道）施用所述化合物的一种或多种治疗有效量，从而激活肠道中的FXR受体，并治疗或预防受试者肠道区域的炎症。
• SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
  申请人：STC. UNM

  公开号：US20130178536A1

  公开（公告）日：2013-07-11

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.
• ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING
  申请人：Salk Institute for Biological Studies

  公开号：US20170066724A1

  公开（公告）日：2017-03-09

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.